A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants
Latest Information Update: 14 Feb 2025
At a glance
- Drugs BCG vaccine (Primary)
- Indications Tuberculosis
- Focus Registrational; Therapeutic Use
- Sponsors Serum Institute of India
- 10 Feb 2025 Status changed from active, no longer recruiting to completed.
- 24 May 2024 Planned End Date changed from 30 Nov 2025 to 31 Dec 2025.
- 24 May 2024 Planned primary completion date changed from 30 Aug 2023 to 31 Dec 2025.